Status:
COMPLETED
Medication Maintenance Therapy in Community Pharmacy Settings
Lead Sponsor:
Lifespan
Collaborating Sponsors:
University of Rhode Island
Conditions:
Opioid-use Disorder
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
The goal of this study is to examine how the pharmacy can better optimize treatment expansion by providing pharmacy-based medication assisted treatment (MAT) for maintenance under a collaborative phar...
Detailed Description
This study will be the first to develop and use a collaborative pharmacy practice agreement (CPA) for medication assisted treatment (MAT) intended for statewide application. This will also be the firs...
Eligibility Criteria
Inclusion
- 18 years of age or older;
- English speaking; currently enrolled at a CODAC site in Rhode Island for the treatment of opioid use disorder;
- maintained on a stable dose of buprenorphine or injectable naltrexone for at least 2 days;
- no stable co-morbid illnesses likely to progress clinically during the pilot study;
- able and willing to provide written informed consent and locator information (working telephone and \>2 contacts) to participate.
Exclusion
- currently pregnant or trying to get pregnant;
- plans to move or leave the state during the study, including pending legal action;
- self reported past year suicide attempt or self-reported past year suicidal thoughts with a plan;
- any condition that, in the researchers' judgment, interferes with safe study participation or adherence to study procedures, including but not limited to a mental, medical or other substance use disorder that is likely to require ongoing, intense clinical management during the pilot study.
Key Trial Info
Start Date :
September 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT03766893
Start Date
September 1 2018
End Date
December 31 2018
Last Update
August 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rhode Island Hospital
Providence, Rhode Island, United States, 02903